ReviewTranslational respiratory medicine2014
Diagnosis and management of interstitial lung disease.
Review in Translational respiratory medicine, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 59 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
59 citing papers in PubMed, 2 syntheses or guidelines pooled it, 177 citations in OpenAlex.
- BAL lymphocytosis as a predictive marker for drug response and long-term outcome in fibrotic ILD: systematic review.BMJ open respiratory research · 2026Pooled it
- Low muscle mass in interstitial lung disease: a systematic review and meta-analysis of prevalence and clinical associations.BMC pulmonary medicine · 2026Pooled it
- Prognostic impact of autoimmune features in interstitial lung disease: a single-center retrospective real-world cohort study.Clinical rheumatology · 2026Article
- Diagnosis of Lung Diseases in the Artificial Intelligence Era.International journal of molecular sciences · 2026Article
- Advances in Targeting HER2 across Cancer Subtypes: A Pan-Tumor Approach.Clinical cancer research : an official journal of the American Association for Cancer Research · 2026Review
- Consensus recommendations for the management of Dato-DXd-associated adverse events in patients with advanced/metastatic NSCLC: insights from a multiregional steering committee.Therapeutic advances in medical oncology · 2026Review
- Progressive fibrotic interstitial lung diseases in India: national challenges and implications for global health policies.Health research policy and systems · 2025Review
- Exploring Interstitial Pneumonia With Autoimmune Features: Case Study Insights and Review of Current Literature.Clinical case reports · 2025Article
- Enhancing Interstitial Lung Disease Diagnoses Through Multimodal AI Integration of Histopathological and CT Image Data.Respirology (Carlton, Vic.) · 2025Article
- Bioimpedance measurements of fibrotic and acutely injured lung tissues.Acta biomaterialia · 2025Article
- Recent Trends and Applications of Nanostructure-based Drug Delivery in Alleviating Chronic Obstructive Pulmonary Disease (COPD).Current drug delivery · 2025Review
- The radiologist's role in detecting systemic anticancer therapy-related interstitial lung disease: an educational review.Insights into imaging · 2024Review
- Comparison of Interstitial Lung Disease Between Antineutrophil Cytoplasmic Antibodies Positive and Negative Patients: A Retrospective Cohort Study.ACR open rheumatology · 2024Article
- Safety profile of trastuzumab deruxtecan in advanced breast cancer: Expert opinion on adverse event management.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2024Review
- Therapeutic Approaches for the Treatment of Interstitial Lung Disease: An Exploratory Review on Molecular Mechanisms.Mini reviews in medicinal chemistry · 2024Review
- Diagnostic yield, safety and therapeutic consequences of myocardial biopsy in clinically suspected fulminant myocarditis unweanable from mechanical circulatory support.Annals of intensive care · 2023Article
- New Frontiers in Therapeutics for Interstitial Lung Diseases.American journal of respiratory and critical care medicine · 2023Article
- Combination of transbronchial cryobiopsy based clinic-radiologic-pathologic strategy and metagenomic next-generation sequencing for differential diagnosis of rapidly progressive diffuse parenchymal lung diseases.Frontiers in cellular and infection microbiology · 2023Article
- Analysis of 12 cases of antineoplastic agents-induced interstitial lung disease.Frontiers in pharmacology · 2023Article
- Epidemiology of interstitial lung disease in patients with metastatic breast cancer at baseline and after treatment with HER2-directed therapy: a real-world data analysis.Breast cancer research and treatment · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The complex tasks of making a confident diagnosis of a specific form of interstitial lung disease (ILD) and formulating a patient-centered, personalized management plan in an attempt to achieve remission or stabilization of the disease process can pose formidable challenges to clinicians. When patients are evaluated for suspected ILD, an accurate diagnosis of the specific form of ILD that a patient has developed must be made to provide the patient with useful prognostic information and to formulate an appropriate management plan that can relieve symptoms and restore or significantly improve quality of life. A well-performed patient history and physical examination provides invaluable information that can be combined with appropriate laboratory testing, imaging, and, if needed, tissue biopsy to reach a confident ILD diagnosis, and high-resolution computed tomography (HRCT) of the thorax is usually a key component of the diagnostic evaluation. If treatment is indicated, many forms of ILD can respond significantly to immunosuppressive anti-inflammatory therapies. However, ILD accompanied by extensive fibrosis may be difficult to treat, and the identification of an effective pharmacologic therapy for idiopathic pulmonary fibrosis (IPF) has remained elusive despite the completion of many phase 3 clinical trials over the past decade. Nonetheless, patients with IPF or advanced forms of non-IPF ILD can benefit significantly from detection and treatment of various co-morbid conditions that are often found in patients (especially the elderly patient), and supportive care (oxygen therapy, pulmonary rehabilitation) can have a beneficial impact on quality of life and symptom palliation. Finally, lung transplantation is an option for patients with progressive, advanced disease that does not respond to other therapies, but only a relatively small subset of patients with end-stage ILD are able to meet wait listing requirements and eventually undergo successful lung transplantation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.